Abstract
Sickle cell anemia (SCA) is one of the most prevalent genetic hematological diseases worldwide. Although procedures such as allogeneic hematopoietic stem cell transplantation or gene editing are curative approaches, limitations related to the cost and risk of these procedures are still barriers to be overcome. In addition, given the different phenotypes of SCA, drug treatment will still b…